Drug Trial Radar · NCT05464784
MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
Last checked: Nov 19, 2026Latest source record: Feb 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Aug 22, 2022
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- MediciNovaIndustry
- Sponsor type
- Industry
- First posted
- Jul 19, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 21 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The design of the Phase 2 clinical trial includes the following elements: * Multi-center, two-arm, randomized, double-blind, placebo-controlled trial to evaluate MN-001 (tipelukast) vs. placebo in approximately 40 patients in the U.S. * Patients will be randomized 1:1 to receive either 500 mg/day of MN-001 (tipelukast) or placebo for 24 weeks. * The co-primary endpoints are (1) change from baseline in liver fat content measured by controlled attenuation parameter (CAP) score at Week 24, and (2) change from baseline in fasting serum triglycerides at Week 24. FibroScan® is a non-invasive, quantitative, and accurate measure of liver fat content commonly used in early phase trials to measure treatment response. * Secondary endpoints include safety and tolerability and changes in lipid profile (HDL-C, LDL-C, and total cholesterol).
Conditions
- Diabetes Mellitus, Type 2
- Hypertriglyceridemia
- Non-Alcoholic Fatty Liver Disease
Interventions
MN-001Drug
MN-001 is a novel, orally bioavailable small molecule compound
MN-001 placeboDrug
The placebo tablet is identical in appearance to the MN-001 tablet, and contains excipients of MN-001.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change in controlled attenuation parameter (CAP) score by sound-based elastography at Week 24Time frame: Week 24
- Mean change from baseline in fasting serum triglyceride levels at Week 24Time frame: Week 24
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Jubilee Clinical Research, Inc.
Las Vegas, Nevada
Pinnacle Clinical Research at South Texas Research Institute
Edinburg, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.